Boxaban (ifetroban) / Vanderbilt University, Cumberland - LARVOL DELTA

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2 | N=56 | Completed | Sponsor: Cumberland Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban (clinicaltrials.gov) - P2 | N=38 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed | Trial completion date: Oct 2023 ➔ Apr 2023

Trial completion • Trial completion date • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease. (PubMed, J Allergy Clin Immunol) - "TP inhibition with ifetroban is well tolerated in AERD patients but may worsen their aspirin-induced reactions, likely due to ifetroban's inhibition of PGE and increase of cysteinyl leukotrienes."

Journal • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2 | N=76 | Active, not recruiting | Sponsor: Cumberland Pharmaceuticals | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban (clinicaltrials.gov) - P2 | N=38 | Active, not recruiting | Sponsor: Brigham and Women's Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2022 ➔ Oct 2023 | Trial primary completion date: Oct 2021 ➔ Oct 2022

Enrollment closed • Trial completion date • Trial primary completion date • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2 | N=76 | Recruiting | Sponsor: Cumberland Pharmaceuticals | Trial completion date: Aug 2022 ➔ Aug 2024 | Trial primary completion date: Apr 2022 ➔ Apr 2024

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Cumberland Pharmaceuticals; Trial primary completion date: Apr 2021 ➔ Apr 2022

Clinical • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban (clinicaltrials.gov) - P2; N=45; Recruiting; Sponsor: Brigham and Women's Hospital; Trial completion date: Feb 2021 ➔ Oct 2022; Trial primary completion date: Oct 2020 ➔ Oct 2021

Trial completion date • Trial primary completion date • Asthma • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Cumberland Pharmaceuticals; Trial completion date: Dec 2021 ➔ Aug 2022

Clinical • Trial completion date • Asthma • Respiratory Diseases

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Cumberland Pharmaceuticals; Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Biosimilar • Immunology • Respiratory Diseases

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban (clinicaltrials.gov) - P2; N=45; Recruiting; Sponsor: Brigham and Women's Hospital; Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Biosimilar • Immunology • Respiratory Diseases

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients (clinicaltrials.gov) - P2; N=30; Not yet recruiting; Sponsor: Cumberland Pharmaceuticals

New P2 trial • Biosimilar • Cardiovascular • Fibrosis • Immunology

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD) (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Cumberland Pharmaceuticals; Trial completion date: Dec 2019 ➔ Dec 2021; Trial primary completion date: Apr 2019 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date